108 related articles for article (PubMed ID: 15125441)
1. Patent alert.
Norman P; Barrett JF
IDrugs; 2004 Apr; 7(4):390-5. PubMed ID: 15125441
[No Abstract] [Full Text] [Related]
2. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
Fernandez DS; Huie JT
Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
[No Abstract] [Full Text] [Related]
3. A new medication to control patulous eustachian disorders.
Hambley W
Am J Otol; 1993 May; 14(3):313-4. PubMed ID: 8372932
[No Abstract] [Full Text] [Related]
4. Issues in the interpretation of 180-day exclusivity.
Lietzan E; Korn DE
Food Drug Law J; 2007; 62(1):49-75. PubMed ID: 17444026
[No Abstract] [Full Text] [Related]
5. Patents related to glycine transporters.
Nat Rev Drug Discov; 2013 Nov; 12(11):821. PubMed ID: 24172325
[No Abstract] [Full Text] [Related]
6. 2004 update--180-day exclusivity under the Hatch-Waxman amendments to the federal Food, Drug, and Cosmetic Act.
Lietzan EK
Food Drug Law J; 2004; 59(4):459-63. PubMed ID: 15875350
[TBL] [Abstract][Full Text] [Related]
7. India emerges as new drug proving ground.
Slater J
Wall St J (East Ed); 2004 Feb; ():B1, B7. PubMed ID: 15290808
[No Abstract] [Full Text] [Related]
8. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
Srivastava D
Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
[No Abstract] [Full Text] [Related]
9. An important addition to the 'Recent Patent' journal series.
Zaman K
Recent Pat Endocr Metab Immune Drug Discov; 2012 Jan; 6(1):1-3. PubMed ID: 22280220
[No Abstract] [Full Text] [Related]
10. TLK-286.
Verschraegen CF; Smith HO; Lee FC; Cathcart C; Norenberg JP
IDrugs; 2004 Aug; 7(8):771-81. PubMed ID: 15334311
[TBL] [Abstract][Full Text] [Related]
11. Therapies targeting pain.
Jahnke U; McGee V
IDrugs; 2008 Jan; 11(1):13-5. PubMed ID: 18175253
[No Abstract] [Full Text] [Related]
12. 27th Annual JPMorgan Healthcare Conference--BioCryst and Emergent Biosolutions.
Croasdell G; Gale S
IDrugs; 2009 Mar; 12(3):149-51. PubMed ID: 19333891
[No Abstract] [Full Text] [Related]
13. BMS-310705 Bristol-Myers Squibb/GBF.
Kolman A
Curr Opin Investig Drugs; 2004 Dec; 5(12):1292-7. PubMed ID: 15648951
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic approaches for Alzheimer's disease.
Jahnke U
IDrugs; 2008 Jan; 11(1):4-6. PubMed ID: 18175250
[No Abstract] [Full Text] [Related]
15. The year's new drugs.
Graul AI; Prous JR
Drug News Perspect; 2005; 18(1):21-36. PubMed ID: 15753973
[TBL] [Abstract][Full Text] [Related]
16. Patent law rulings work in favor of generics.
Sipkoff M
Manag Care; 2007 Sep; 16(9):12, 14. PubMed ID: 17969743
[No Abstract] [Full Text] [Related]
17. Therapeutic research for depression and insomnia.
McGee V
IDrugs; 2008 Jan; 11(1):10-2. PubMed ID: 18175252
[No Abstract] [Full Text] [Related]
18. [Why patent-protected drugs' cost efficiency should be compared with generic preparations].
Berggren F; Lundin D; Ramsberg J
Lakartidningen; 2006 Jan 25-31; 103(4):223-4. PubMed ID: 16491555
[No Abstract] [Full Text] [Related]
19. MS-209 Schering.
Robert J
Curr Opin Investig Drugs; 2004 Dec; 5(12):1340-7. PubMed ID: 15648956
[TBL] [Abstract][Full Text] [Related]
20. AE-941 (AEterna).
Dredge K
Curr Opin Investig Drugs; 2004 Jun; 5(6):668-77. PubMed ID: 15242256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
